Yale New Haven Health, MultiCare lean on internal experts to evaluate Aduhelm

Hospitals are in limbo as they await Medicare's preliminary decision on whether it will cover Aduhelm; that ruling is expected in January with a final decision anticipated in April. As they await guidance, some health systems are reviewing Biogen's controversial Alzheimer's drug on their own.

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive